(Reuters) - Moderna Inc (O:MRNA) plans to price its experimental coronavirus vaccine in a way that ensures broad access, it said on Wednesday, adding that it did not intend to conduct late-stage trials of the shot outside the United States.
Chief Executive Officer Stéphane Bancel declined to comment on the specific price of the vaccine on a conference call with analysts.
The Financial Times reported on Tuesday, citing unnamed sources, that the company was planning to price the vaccine at $50 (38.5 pounds) to $60 per course, at least $11 more than another vaccine from Pfizer Inc (N:PFE) and BioNTech (F:22UAy).